• Oculis flagged licaminlimab as a lead program ahead of an Eyecelerator @ AAO 2026 presentation on Oct. 8.
• Topline results from the PREDICT-1 registrational symptoms trial are expected around year-end, not yet presented.
• The readout is positioned as a key step toward a genotype-guided treatment approach for TNFR1-mediated dry eye disease.
• Oculis also plans to sponsor AAO’s Neuro-Ophthalmology Subspecialty Day on Oct. 9, underscoring its strategic focus in the field.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oculis Holding AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070200OMX_____CNEWS_EN_GNW1001276646_en) on October 07, 2026, and is solely responsible for the information contained therein.